person · Reporting owner

BARER SOL J

Disclosed activity across 8 companies

Tapewire entity: 40719
SEC CIK: 0001247015

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Avalo Therapeutics, Inc.CERC · Entity 4936	Director	June 15, 2021	June 17, 2021
CONTRAFECT CorpCFRX · Entity 116797	Director	May 17, 2022	May 18, 2022
InspireMD, Inc.NSPR · Entity 7318	Director	December 07, 2016	December 08, 2016
NexImmune, Inc.NEXI · Entity 89921	Director	July 05, 2023	July 07, 2023
PDS Biotechnology CorpEDGE · Entity 7939	Director	March 15, 2019	March 18, 2019
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063	Director	June 05, 2026	June 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Avalo Therapeutics, Inc.

Report date June 15, 2021 · Filed June 17, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2031-06-15	Direct	40,000	Reported balance After 2021-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-15 · Grant · Acquired 40,000 · Balance 40,000 F1: This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date.

CONTRAFECT Corp

Report date May 17, 2022 · Filed May 18, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2032-05-17	Direct	42,000	Reported balance After 2022-05-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-05-17 · Grant · Acquired 42,000 · Balance 42,000 F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date.

Filing footnotes · ownership attribution and instrument terms

F1: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date.

InspireMD, Inc.

Report date December 07, 2016 · Filed December 08, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2026-12-07	Direct	20,000	Reported balance After 2016-12-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-12-07 · Grant · Acquired 20,000 · Balance 20,000 F1: The options vest in three equal annual installments, with 1/3 becoming exercisable on each of December 7, 2017, December 7, 2018 and December 7, 2019, subject to Mr. Barer's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest in three equal annual installments, with 1/3 becoming exercisable on each of December 7, 2017, December 7, 2018 and December 7, 2019, subject to Mr. Barer's continued service.

NexImmune, Inc.

Report date July 05, 2023 · Filed July 07, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2033-07-04	Direct	44,983	Reported balance After 2023-07-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-07-05 · Grant · Acquired 44,983 · Balance 44,983

PDS Biotechnology Corp

Report date March 15, 2019 · Filed March 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Spouse	678,075	Reported balance After 2019-03-15 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-03-15 · Exercise / conversion · Acquired 20,000 · Balance 678,075 F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F2: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-03-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-03-15 · Exercise / conversion · Disposed 20,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F4: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F5: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F2: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F3: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F4: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F5: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date June 05, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	448,011	Reported balance After 2026-06-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-05 · Exercise / conversion · Acquired 21,739 · Balance 448,011 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-05 · Exercise / conversion · Disposed 21,739 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aegerion Pharmaceuticals, Inc.

Report date November 29, 2016 · Filed December 01, 2016

Section 16 reporting ended · disclosed 2016-12-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-11-29 transaction · row 1 1 source row Row 1 · 2016-11-29 · Disposition to issuer · Disposed 29,890 · Balance 0 F1: Disposed of in exchange for 30,665 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.25 · Expires 2021-05-05	Direct	Reported balance After 2016-11-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-11-29 · Disposition to issuer · Disposed 19,927 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.64 · Expires 2021-06-01	Direct	Reported balance After 2016-11-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-11-29 · Disposition to issuer · Disposed 9,988 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2022-06-05	Direct	Reported balance After 2016-11-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-11-29 · Disposition to issuer · Disposed 12,854 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.73 · Expires 2023-06-26	Direct	Reported balance After 2016-11-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-11-29 · Disposition to issuer · Disposed 14,700 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.55 · Expires 2024-06-26	Direct	Reported balance After 2016-11-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-11-29 · Disposition to issuer · Disposed 5,012 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.98 · Expires 2025-06-26	Direct	Reported balance After 2016-11-29 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2016-11-29 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of in exchange for 30,665 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."

F2: Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a QLT common share on November 28, 2016) was cancelled without any payment or other consideration therefor.

Aevi Genomic Medicine, LLC

Report date February 03, 2020 · Filed February 05, 2020

Section 16 reporting ended · disclosed 2020-02-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2023-09-13	Direct	Reported balance After 2020-02-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger").
Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2023-01-02	Direct	Reported balance After 2020-02-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-02-03 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: This option, which became exercisable on January 2, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2024-01-02	Direct	Reported balance After 2020-02-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-02-03 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: This option, which became exercisable on January 2, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2025-02-18	Direct	Reported balance After 2020-02-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-02-03 · Disposition to issuer · Disposed 80,000 · Balance 0 F4: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2026-04-15	Direct	Reported balance After 2020-02-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-02-03 · Disposition to issuer · Disposed 80,000 · Balance 0 F5: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-06-22	Direct	Reported balance After 2020-02-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-02-03 · Disposition to issuer · Disposed 80,000 · Balance 0 F6: This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2028-04-17	Direct	Reported balance After 2020-02-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-02-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F7: This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2023-09-13	IndirectBy the Sol J. Barer 2013 Grantor Retained Annuity Trust III	Reported balance After 2020-02-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger").
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2022-10-17	Direct	Reported balance After 2020-02-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-02-03 · Disposition to issuer · Disposed 74,912 · Balance 0 F8: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void.

Filing footnotes · ownership attribution and instrument terms

F1: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger").

F2: This option, which became exercisable on January 2, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.

F3: This option, which became exercisable on January 2, 2015, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.

F4: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.

F5: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.

F6: This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.

F7: This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.

F8: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2026 Filed Jun 8, 2026 20:07 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	21,739	$0.00	$0.00	Disclosure SEC source: 0001193125-26-261715 · ownership.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,739 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F3 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 05, 2026 Filed Jun 8, 2026 20:07 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	21,739	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-261715 · ownership.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
May 28, 2026 Filed Jun 1, 2026 20:03 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	10,863	$0.00	$0.00	Disclosure SEC source: 0001193125-26-251384 · ownership.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,863 Underlying: Ordinary Shares · 10,863 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F2 · derivative.expiration_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 06, 2025 Filed Jun 9, 2025 20:05 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	17,158	$0.00	$0.00	Disclosure SEC source: 0000950170-25-083706 · ownership.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,158 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F3 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 06, 2025 Filed Jun 9, 2025 20:05 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	17,158	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-083706 · ownership.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:05 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	21,739	$0.00	$0.00	Disclosure SEC source: 0000950170-25-083706 · ownership.xml · derivative · entry 3 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,739 Underlying: Ordinary Shares · 21,739 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F4 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 15, 2024 Filed Jun 17, 2024 11:14 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	37,598	$0.00	$0.00	Disclosure SEC source: 0000950170-24-074001 · ownership.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 37,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024. F3 · derivative.expiration_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 15, 2024 Filed Jun 17, 2024 11:14 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	37,598	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-074001 · ownership.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
June 06, 2024 Filed Jun 10, 2024 11:31 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	17,158	$0.00	$0.00	Disclosure SEC source: 0000950170-24-071062 · ownership.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,158 Underlying: Ordinary Shares · 17,158 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F2 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
August 04, 2023 Filed Aug 7, 2023 20:02 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	28,162	$0.00	$0.00	Disclosure SEC source: 0001209191-23-044769 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 28,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023. F3 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
August 04, 2023 Filed Aug 7, 2023 20:02 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	28,162	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-044769 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
July 05, 2023 Filed Jul 7, 2023 20:16 UTC	NexImmune, Inc. NEXI · Entity 89921	GrantStock Option (right to buy) · Derivative	44,983	$0.00 Strike: $0.29	$0.00	Disclosure SEC source: 0000950170-23-032245 · ownership.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,983 Underlying: Common Stock · 44,983 shares Expires 2033-07-04 Read SEC document
June 15, 2023 Filed Jun 20, 2023 11:31 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	37,598	$0.00	$0.00	Disclosure SEC source: 0001209191-23-038217 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,598 Underlying: Ordinary Shares · 37,598 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024. F2 · derivative.expiration_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
April 04, 2023 Filed Apr 7, 2023 00:34 UTC	NexImmune, Inc. NEXI · Entity 89921	GrantStock Option (right to buy) · Derivative	155,900	Not disclosed Strike: $1.64	Not disclosed	Disclosure SEC source: 0001209191-23-023681 · doc4.xml · derivative · entry 6 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,900 Underlying: Common Stock · 155,900 shares Expires 2030-03-04 F3 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. Mr. Barer has exercised his right to purchase 50,000 shares subject to the original option. F3 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. Mr. Barer has exercised his right to purchase 50,000 shares subject to the original option. F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. Mr. Barer has exercised his right to purchase 50,000 shares subject to the original option. Read SEC document
April 04, 2023 Filed Apr 7, 2023 00:34 UTC	NexImmune, Inc. NEXI · Entity 89921	Disposition to issuerStock Option (right to buy) · Derivative	155,900	Not disclosed Strike: $5.17	Not disclosed	Disclosure SEC source: 0001209191-23-023681 · doc4.xml · derivative · entry 5 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,900 shares Expires 2030-03-04 F3 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. Mr. Barer has exercised his right to purchase 50,000 shares subject to the original option. F3 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. Mr. Barer has exercised his right to purchase 50,000 shares subject to the original option. F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 5, 2020, of which all of the shares subject to such option have vested. Mr. Barer has exercised his right to purchase 50,000 shares subject to the original option. Read SEC document
April 04, 2023 Filed Apr 7, 2023 00:34 UTC	NexImmune, Inc. NEXI · Entity 89921	GrantStock Option (right to buy) · Derivative	19,113	Not disclosed Strike: $1.64	Not disclosed	Disclosure SEC source: 0001209191-23-023681 · doc4.xml · derivative · entry 4 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,113 Underlying: Common Stock · 19,113 shares Expires 2031-02-10 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. Read SEC document
April 04, 2023 Filed Apr 7, 2023 00:34 UTC	NexImmune, Inc. NEXI · Entity 89921	Disposition to issuerStock Option (right to buy) · Derivative	19,113	Not disclosed Strike: $17.00	Not disclosed	Disclosure SEC source: 0001209191-23-023681 · doc4.xml · derivative · entry 3 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,113 shares Expires 2031-02-10 F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 11, 2021, of which all of the shares subject to such option have vested. Read SEC document
April 04, 2023 Filed Apr 7, 2023 00:34 UTC	NexImmune, Inc. NEXI · Entity 89921	GrantStock Option (right to buy) · Derivative	61,678	Not disclosed Strike: $1.64	Not disclosed	Disclosure SEC source: 0001209191-23-023681 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,678 Underlying: Common Stock · 61,678 shares Expires 2032-06-12 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Barer's continued service on such vesting date. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Barer's continued service on such vesting date. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Barer's continued service on such vesting date. Read SEC document
April 04, 2023 Filed Apr 7, 2023 00:34 UTC	NexImmune, Inc. NEXI · Entity 89921	Disposition to issuerStock Option (right to buy) · Derivative	61,678	Not disclosed Strike: $1.82	Not disclosed	Disclosure SEC source: 0001209191-23-023681 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,678 shares Expires 2032-06-12 F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Barer's continued service on such vesting date. F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Barer's continued service on such vesting date. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on June 13, 2022, of which all of the shares subject to such option will vest on June 13, 2023, subject to Mr. Barer's continued service on such vesting date. Read SEC document
March 30, 2023 Filed Mar 31, 2023 20:56 UTC	NexImmune, Inc. NEXI · Entity 89921	PurchaseCommon Stock	400,000	$0.41	$164,120.00	Disclosure SEC source: 0001209191-23-021889 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,217,814 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4000 to $0.4200, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Excludes 175,012 shares of common stock underlying options that are currently exercisable. Read SEC document
November 17, 2022 Filed Nov 18, 2022 01:40 UTC	NexImmune, Inc. NEXI · Entity 89921	PurchaseCommon Stock	75,000	$0.48	$35,917.50	Disclosure SEC source: 0001209191-22-057746 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,817,814 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4754 to $0.4890, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price F2 · balance_after: Excludes 175,012 shares of common stock underlying options that are currently exercisable. Read SEC document
November 16, 2022 Filed Nov 18, 2022 01:40 UTC	NexImmune, Inc. NEXI · Entity 89921	PurchaseCommon Stock	125,000	$0.48	$60,300.00	Disclosure SEC source: 0001209191-22-057746 · doc4.xml · nonDerivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,742,814 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4557 to $0.4900, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price F2 · balance_after: Excludes 175,012 shares of common stock underlying options that are currently exercisable. Read SEC document
August 04, 2022 Filed Aug 8, 2022 11:10 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	28,162	$0.00	$0.00	Disclosure SEC source: 0001209191-22-044689 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,162 Underlying: Ordinary Shares · 28,162 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 14, 2022 Filed Jun 16, 2022 11:32 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	25,791	$0.00	$0.00	Disclosure SEC source: 0001209191-22-037243 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,791 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022. F3 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vested on June 14, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 14, 2022 Filed Jun 16, 2022 11:32 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	25,791	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-037243 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
June 13, 2022 Filed Jun 15, 2022 20:57 UTC	NexImmune, Inc. NEXI · Entity 89921	GrantStock Option (Right to Buy) · Derivative	61,678	$0.00 Strike: $1.82	$0.00	Disclosure SEC source: 0001209191-22-037010 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,678 Underlying: Common Stock · 61,678 shares Expires 2032-06-12 Read SEC document
June 02, 2022 Filed Jun 2, 2022 23:41 UTC	NexImmune, Inc. NEXI · Entity 89921	PurchaseCommon Stock	20,720	$2.22	$46,099.93	Disclosure SEC source: 0001209191-22-033727 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,617,814 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.09 to $2.35, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Excludes 175,012 shares of common stock underlying options that are currently exercisable. Read SEC document
June 01, 2022 Filed Jun 2, 2022 23:41 UTC	NexImmune, Inc. NEXI · Entity 89921	PurchaseCommon Stock	40,000	$2.35	$94,160.00	Disclosure SEC source: 0001209191-22-033727 · doc4.xml · nonDerivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,597,094 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.23 to $2.59, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Excludes 175,012 shares of common stock underlying options that are currently exercisable. Read SEC document
May 31, 2022 Filed Jun 2, 2022 23:41 UTC	NexImmune, Inc. NEXI · Entity 89921	PurchaseCommon Stock	39,280	$2.19	$85,893.58	Disclosure SEC source: 0001209191-22-033727 · doc4.xml · nonDerivative · entry 3 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,557,094 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.95 to $2.46, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Excludes 175,012 shares of common stock underlying options that are currently exercisable. Read SEC document
May 17, 2022 Filed May 18, 2022 17:59 UTC	CONTRAFECT Corp CFRX · Entity 116797	GrantOptions (Right to Buy) · Derivative	42,000	$3.35 Strike: $3.35	$140,700.00	Disclosure SEC source: 0001209191-22-030193 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: Grant award made under the ContraFect Corporation 2014 Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. Read SEC document
March 23, 2022 Filed Mar 24, 2022 20:15 UTC	NexImmune, Inc. NEXI · Entity 89921	PurchaseCommon Stock	10,000	$2.67	$26,653.00	Disclosure SEC source: 0001209191-22-020914 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517,814 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.43 to $2.785, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Excludes 175,012 shares of common stock underlying options that are currently exercisable. Read SEC document
March 22, 2022 Filed Mar 23, 2022 20:15 UTC	NexImmune, Inc. NEXI · Entity 89921	PurchaseCommon Stock	30,000	$2.41	$72,300.00	Disclosure SEC source: 0001209191-22-020766 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507,814 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.13 to $2.69, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Excludes 175,012 shares of common stock underlying options that are currently exercisable. Read SEC document
March 21, 2022 Filed Mar 22, 2022 20:15 UTC	NexImmune, Inc. NEXI · Entity 89921	PurchaseCommon Stock	30,000	$2.14	$64,080.00	Disclosure SEC source: 0001209191-22-020522 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,477,814 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.05 to $2.235, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Excludes 175,012 shares of common stock underlying options that are currently exercisable. Read SEC document
March 18, 2022 Filed Mar 21, 2022 20:10 UTC	NexImmune, Inc. NEXI · Entity 89921	PurchaseCommon Stock	30,000	$2.11	$63,210.00	Disclosure SEC source: 0001209191-22-020256 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,447,814 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.96 to $2.28, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Excludes 175,012 shares of common stock underlying options that are currently exercisable. Read SEC document
December 21, 2021 Filed Dec 22, 2021 13:00 UTC	NexImmune, Inc. NEXI · Entity 89921	Exercise / conversionStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $5.17	$0.00	Disclosure SEC source: 0001209191-21-070879 · doc4.xml · derivative · entry 4 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,900 Underlying: Common Stock · 50,000 shares Expires 2030-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 21, 2021 Filed Dec 22, 2021 13:00 UTC	NexImmune, Inc. NEXI · Entity 89921	Exercise / conversionCommon Stock	50,000	$5.17	$258,500.00	Disclosure SEC source: 0001209191-21-070879 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,417,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2021 Filed Jun 17, 2021 20:33 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $3.56	$0.00	Disclosure SEC source: 0001192482-21-000521 · edgar.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-15 F1 · shares: This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date. Read SEC document
June 14, 2021 Filed Jun 16, 2021 12:10 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	GrantRestricted Share Units · Derivative	25,791	$0.00	$0.00	Disclosure SEC source: 0001209191-21-040805 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,791 Underlying: Ordinary Shares · 25,791 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F2 · derivative.expiration_date: Restricted share units were granted on June 14, 2021 and vest on June 14, 2022. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 09, 2021 Filed Jun 10, 2021 11:39 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	22,565	$0.00	$0.00	Disclosure SEC source: 0001209191-21-039367 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,565 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021. F3 · derivative.expiration_date: Restricted share units were granted on June 9, 2020 and vested on June 9, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 09, 2021 Filed Jun 10, 2021 11:39 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	22,565	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-039367 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
June 05, 2021 Filed Jun 8, 2021 11:23 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionRestricted Share Units · Derivative	17,565	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038811 · doc4.xml · derivative · entry 2 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,565 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021. F3 · derivative.expiration_date: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 05, 2021 Filed Jun 8, 2021 11:23 UTC	TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063	Exercise / conversionOrdinary Shares	17,565	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-038811 · doc4.xml · nonDerivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document
May 18, 2021 Filed May 20, 2021 19:43 UTC	CONTRAFECT Corp CFRX · Entity 116797	GrantOptions (Right to Buy) · Derivative	25,000	$0.00 Strike: $3.86	$0.00	Disclosure SEC source: 0001209191-21-034647 · doc4.xml · derivative · entry 1 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-05-18 F1 · derivative.exercise_date: Grant award made under the ContraFect Corporation Omnibus Incentive Plan. Grant vests over one year, 25% at the end of each quarter following the vesting commencement date. Read SEC document
February 17, 2021 Filed Feb 19, 2021 21:20 UTC	NexImmune, Inc. NEXI · Entity 89921	ConversionSeries A Preferred Stock · Derivative	217,570	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012354 · doc4.xml · derivative · entry 13 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Joshua Barer Disclosed balance after: 0 Underlying: Common Stock · 217,570 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F7 · derivative.expiration_date: Not applicable. F5 · ownership.nature: Mr. Barer is the father of Joshua Barer. Mr. Sol Barer disclaims beneficial ownership of the securities held by Joshua Barer except to the extent of his pecuniary interest therein. Read SEC document
February 17, 2021 Filed Feb 19, 2021 21:20 UTC	NexImmune, Inc. NEXI · Entity 89921	ConversionConvertible Promissory Note · Derivative	Not disclosed	Not disclosed	$2,875,458.00	Disclosure SEC source: 0001209191-21-012354 · doc4.xml · derivative · entry 12 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by B&S NexImmune Holdco LLC Disclosed balance after: 0 Underlying: Common Stock · 337,365 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On February 17, 2021 (the "Closing"), the convertible promissory notes (the "Notes") became automatically convertible into shares of the Issuer's common stock. At the Closing, the principal amount of the Notes, plus accrued but unpaid interest thereon through February 17, 2021, converted into shares of the Issuer's common stock by dividing the principal and accrued but unpaid interest under such Note by the price per share obtained by dividing $125,000,000 by the Company's fully-diluted capitalization immediately prior to the IPO, assuming exercise or conversion of all convertible securities of the Company but excluding any shares issuable upon conversion of the Notes. F3 · price: On February 17, 2021 (the "Closing"), the convertible promissory notes (the "Notes") became automatically convertible into shares of the Issuer's common stock. At the Closing, the principal amount of the Notes, plus accrued but unpaid interest thereon through February 17, 2021, converted into shares of the Issuer's common stock by dividing the principal and accrued but unpaid interest under such Note by the price per share obtained by dividing $125,000,000 by the Company's fully-diluted capitalization immediately prior to the IPO, assuming exercise or conversion of all convertible securities of the Company but excluding any shares issuable upon conversion of the Notes. F3 · derivative.exercise_date: On February 17, 2021 (the "Closing"), the convertible promissory notes (the "Notes") became automatically convertible into shares of the Issuer's common stock. At the Closing, the principal amount of the Notes, plus accrued but unpaid interest thereon through February 17, 2021, converted into shares of the Issuer's common stock by dividing the principal and accrued but unpaid interest under such Note by the price per share obtained by dividing $125,000,000 by the Company's fully-diluted capitalization immediately prior to the IPO, assuming exercise or conversion of all convertible securities of the Company but excluding any shares issuable upon conversion of the Notes. F7 · derivative.expiration_date: Not applicable. F2 · ownership.nature: Mr. Barer is the father of Joshua Barer, who is the sole manager of B&S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer is also a member of Barer & Son Capital, LLC, which is a member of B&S NexImmune Holdco LLC, but he does not have voting or dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer disclaims beneficial ownership of the securities held by B&S NexImmune Holdco LLC except to the extent of his pecuniary interest therein. Read SEC document
February 17, 2021 Filed Feb 19, 2021 21:20 UTC	NexImmune, Inc. NEXI · Entity 89921	ConversionSeries A3 Preferred Stock · Derivative	82,204	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012354 · doc4.xml · derivative · entry 11 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by B&S NexImmune Holdco LLC Disclosed balance after: 0 Underlying: Common Stock · 82,204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F7 · derivative.expiration_date: Not applicable. F2 · ownership.nature: Mr. Barer is the father of Joshua Barer, who is the sole manager of B&S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer is also a member of Barer & Son Capital, LLC, which is a member of B&S NexImmune Holdco LLC, but he does not have voting or dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer disclaims beneficial ownership of the securities held by B&S NexImmune Holdco LLC except to the extent of his pecuniary interest therein. Read SEC document
February 17, 2021 Filed Feb 19, 2021 21:20 UTC	NexImmune, Inc. NEXI · Entity 89921	ConversionSeries A2 Preferred Stock · Derivative	164,408	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012354 · doc4.xml · derivative · entry 10 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held B&S NexImmune Holdco LLC Disclosed balance after: 0 Underlying: Common Stock · 164,408 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F7 · derivative.expiration_date: Not applicable. F2 · ownership.nature: Mr. Barer is the father of Joshua Barer, who is the sole manager of B&S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer is also a member of Barer & Son Capital, LLC, which is a member of B&S NexImmune Holdco LLC, but he does not have voting or dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer disclaims beneficial ownership of the securities held by B&S NexImmune Holdco LLC except to the extent of his pecuniary interest therein. Read SEC document
February 17, 2021 Filed Feb 19, 2021 21:20 UTC	NexImmune, Inc. NEXI · Entity 89921	ConversionSeries A Preferred Stock · Derivative	894,036	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012354 · doc4.xml · derivative · entry 9 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by B&S NexImmune Holdco LLC Disclosed balance after: 0 Underlying: Common Stock · 894,036 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F7 · derivative.expiration_date: Not applicable. F2 · ownership.nature: Mr. Barer is the father of Joshua Barer, who is the sole manager of B&S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer is also a member of Barer & Son Capital, LLC, which is a member of B&S NexImmune Holdco LLC, but he does not have voting or dispositive control over the shares held by B&S NexImmune Holdco LLC. Mr. Sol Barer disclaims beneficial ownership of the securities held by B&S NexImmune Holdco LLC except to the extent of his pecuniary interest therein. Read SEC document
February 17, 2021 Filed Feb 19, 2021 21:20 UTC	NexImmune, Inc. NEXI · Entity 89921	ConversionSeries A Preferred Stock · Derivative	800,182	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012354 · doc4.xml · derivative · entry 8 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800,182 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F6 · derivative.exercise_date: The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering. F7 · derivative.expiration_date: Not applicable. Read SEC document
February 17, 2021 Filed Feb 19, 2021 21:20 UTC	NexImmune, Inc. NEXI · Entity 89921	ConversionCommon Stock	217,570	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012354 · doc4.xml · nonDerivative · entry 7 BARER SOL J · CIK 0001247015 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Joshua Barer Disclosed balance after: 346,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 1-for-1 basis. F5 · ownership.nature: Mr. Barer is the father of Joshua Barer. Mr. Sol Barer disclaims beneficial ownership of the securities held by Joshua Barer except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.